UCH‐L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease

Aggresomes are associated with many neurodegenerative disorders, including Parkinson's disease, and polyglutamine disorders such as Huntington's disease. These inclusions commonly contain ubiquitylated proteins. The stage at which these proteins are ubiquitylated remains unclear. A malfunction of the ubiquitin/proteasome system (UPS) may be associated with their formation. Conversely, it may reflect an unsuccessful attempt by the cell to remove them. Previously, we demonstrated that overexpression of Parkin, a ubiquitin‐protein ligase associated with autosomal recessive juvenile Parkinsonism, generates aggresome‐like inclusions in UPS compromised cells. Mutations in the de‐ubiquitylating enzyme, UCH‐L1, cause a rare form of Parkinsonism. We now demonstrate that overexpression of UCH‐L1 also forms ribbon‐like aggresomes in response to proteasomal inhibition. Disease‐associated mutations, which affect enzymatic activities, significantly increased the number of inclusions. UCH‐L1 aggresomes co‐localized with ubiquitylated proteins, HSP70, γ‐tubulin and, to a lesser extent, the 20S proteasome and the chaperone BiP. Similar to Parkin inclusions, we found UCH‐L1 aggresomes to be surrounded by a tubulin rather than a vimentin cage‐like structure. Furthermore, UCH‐L1 aggregates with Parkin and α‐synuclein in some, but not all inclusions, suggesting the heterogeneous nature of these inclusion bodies. This study provides additional evidence that aggregation‐prone proteins are likely to recruit UPS components in an attempt to clear proteins from failing proteasomes. Furthermore, UCH‐L1 accumulation is likely to play a pathological role in inclusion formation in Parkinson's disease.

[1]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  Takeshi Iwatsubo,et al.  Aggresomes Formed by α-Synuclein and Synphilin-1 Are Cytoprotective* , 2004, Journal of Biological Chemistry.

[3]  K. Baek,et al.  DUB-1A, a Novel Deubiquitinating Enzyme Subfamily Member, Is Polyubiquitinated and Cytokine-inducible in B-lymphocytes* , 2004, Journal of Biological Chemistry.

[4]  Barrington G. Burnett,et al.  The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. , 2003, Human molecular genetics.

[5]  P. Lockhart,et al.  RING finger 1 mutations in Parkin produce altered localization of the protein. , 2003, Human molecular genetics.

[6]  B. Ghetti,et al.  Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function* , 2003, Journal of Biological Chemistry.

[7]  S. Endo,et al.  A novel ubiquitin‐specific protease, synUSP, is localized at the post‐synaptic density and post‐synaptic lipid raft , 2003, Journal of neurochemistry.

[8]  G. Scott,et al.  Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin. , 2003, Molecular biology of the cell.

[9]  N. Wood,et al.  Parkin is recruited into aggresomes in a stress-specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkin's effect on neuronal survival. , 2003, Human molecular genetics.

[10]  David W. Miller,et al.  L166P Mutant DJ-1, Causative for Recessive Parkinson's Disease, Is Degraded through the Ubiquitin-Proteasome System* , 2003, Journal of Biological Chemistry.

[11]  Hiroshi Nakayama,et al.  PGP9.5 overexpression in esophageal squamous cell carcinoma. , 2003, Hepato-gastroenterology.

[12]  Kaori Nishikawa,et al.  Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. , 2003, Human molecular genetics.

[13]  C. V. van Duijn,et al.  Parkinson's disease: piecing together a genetic jigsaw. , 2003, Brain : a journal of neurology.

[14]  James E Bear,et al.  A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Hirokawa,et al.  Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. , 2003, Biochemical and biophysical research communications.

[16]  P. Amouyel,et al.  S18Y polymorphism in the UCH‐L1 gene and Parkinson's disease: Evidence for an age‐dependent relationship , 2003, Movement disorders : official journal of the Movement Disorder Society.

[17]  C. Warren Olanow,et al.  Altered Proteasomal Function in Sporadic Parkinson's Disease , 2003, Experimental Neurology.

[18]  M. Mouradian,et al.  Parkin Accumulation in Aggresomes Due to Proteasome Impairment* , 2002, The Journal of Biological Chemistry.

[19]  D. Perl,et al.  Aggresome‐related biogenesis of Lewy bodies , 2002, The European journal of neuroscience.

[20]  P. Lansbury,et al.  The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect α-Synuclein Degradation and Parkinson's Disease Susceptibility , 2002, Cell.

[21]  N. Shastri,et al.  ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum , 2002, Nature.

[22]  R. Mayer,et al.  The ubiquitin-proteasome pathway of intracellular proteolysis. , 2002, Essays in biochemistry.

[23]  A. Destée,et al.  Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease , 2002, Neuroscience Letters.

[24]  E. Sztul,et al.  Hassles with Taking Out the Garbage: Aggravating Aggresomes , 2002, Traffic.

[25]  B. Hyman,et al.  Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. , 2002, The American journal of pathology.

[26]  S. Shin,et al.  Formation and Removal of α-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors* , 2002, The Journal of Biological Chemistry.

[27]  C. Woods,et al.  Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36 , 2001, Journal of medical genetics.

[28]  L. Petrucelli,et al.  Co-association of parkin and α-synuclein , 2001 .

[29]  D. Sulzer,et al.  Proteasomal inhibition leads to formation of ubiquitin/α‐synuclein‐immunoreactive inclusions in PC12 cells , 2001, Journal of neurochemistry.

[30]  Barry Halliwell,et al.  Failure of the ubiquitin–proteasome system in Parkinson's disease , 2001, Nature Reviews Neuroscience.

[31]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[32]  A. Markham,et al.  Features of the Parkin/Ariadne-like Ubiquitin Ligase, HHARI, That Regulate Its Interaction with the Ubiquitin-conjugating Enzyme, UbcH7* , 2001, The Journal of Biological Chemistry.

[33]  M. Sherman,et al.  Intracellular Aggregation of Polypeptides with Expanded Polyglutamine Domain Is Stimulated by Stress-Activated Kinase Mekk1 , 2001, The Journal of cell biology.

[34]  H. Lehrach,et al.  Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. , 2001, Molecular biology of the cell.

[35]  R. Takahashi,et al.  Implications of Protein Degradation in Aging , 2001, Annals of the New York Academy of Sciences.

[36]  A. Bentivoglio,et al.  Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. , 2001, American journal of human genetics.

[37]  A. Weissman Ubiquitin and proteasomes: Themes and variations on ubiquitylation , 2001, Nature Reviews Molecular Cell Biology.

[38]  A. Goldberg,et al.  Cellular Defenses against Unfolded Proteins A Cell Biologist Thinks about Neurodegenerative Diseases , 2001, Neuron.

[39]  K. McNaught,et al.  Proteasomal function is impaired in substantia nigra in Parkinson's disease , 2001, Neuroscience Letters.

[40]  Giladi,et al.  Failure to find mutations in ubiquitin carboxy-terminal hydrolase L1 gene in familial Parkinson's disease. , 2000, Parkinsonism & related disorders.

[41]  S. Kubo,et al.  Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. , 2000, Parkinsonism & related disorders.

[42]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[43]  A. Markham,et al.  Regulation and function of the interaction between the APC tumour suppressor protein and EB1 , 2000, Oncogene.

[44]  S. Warren,et al.  Aberrant Protein Deposition and Neurological Disease* , 1999, The Journal of Biological Chemistry.

[45]  S. H. Baek,et al.  Deubiquitinating enzymes: their diversity and emerging roles. , 1999, Biochemical and biophysical research communications.

[46]  Harry T Orr,et al.  Mutation of the E6-AP Ubiquitin Ligase Reduces Nuclear Inclusion Frequency While Accelerating Polyglutamine-Induced Pathology in SCA1 Mice , 1999, Neuron.

[47]  M. Farrer,et al.  Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson’s disease , 1999, Neurology.

[48]  E. Sztul,et al.  Characterization and Dynamics of Aggresome Formation by a Cytosolic Gfp-Chimera✪ , 1999, The Journal of cell biology.

[49]  S. Goodman,et al.  PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. , 1999, The American journal of pathology.

[50]  S. Minoshima,et al.  Immunohistochemical and subcellular localization of parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients , 1999, Annals of neurology.

[51]  R. Kopito,et al.  Aggresomes: A Cellular Response to Misfolded Proteins , 1998, The Journal of cell biology.

[52]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[53]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[54]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[55]  A. Goldberg,et al.  Proteasome inhibitors: valuable new tools for cell biologists. , 1998, Trends in cell biology.

[56]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[57]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[58]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[59]  A. Goldberg,et al.  Proteasome Inhibition Leads to a Heat-shock Response, Induction of Endoplasmic Reticulum Chaperones, and Thermotolerance* , 1997, The Journal of Biological Chemistry.

[60]  Hidefumi Ito,et al.  Immunocytochemical Co‐localization of the Proteasome in Ubiquitinated Structures in Neurodegenerative Diseases and the Elderly , 1997, Journal of neuropathology and experimental neurology.

[61]  S. Nigam,et al.  Perturbations in maturation of secretory proteins and their association with endoplasmic reticulum chaperones in a cell culture model for epithelial ischemia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Hisashi Ito,et al.  Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. , 1996, Journal of biochemistry.

[63]  R. Baker,et al.  Control of Cell Fate by a Deubiquitinating Enzyme Encoded by the fat facets Gene , 1995, Science.

[64]  M. Fujimuro,et al.  Production and characterization of monoclonal antibodies specific to multi‐ubiquitin chains of polyubiquitinated proteins , 1994, FEBS letters.

[65]  D. Dickson,et al.  Pathology and Biology of the Lewy Body , 1993, Journal of neuropathology and experimental neurology.

[66]  J. Lowe,et al.  Ubiquitin carboxyl‐terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases , 1990, The Journal of pathology.

[67]  K D Wilkinson,et al.  The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. , 1989, Science.

[68]  C. Olanow,et al.  Proteolytic stress: A unifying concept for the etiopathogenesis of Parkinson's disease , 2003, Annals of neurology.

[69]  C. Olanow,et al.  Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. , 2002, Neuroscience letters.

[70]  A. Nakao,et al.  PGP9.5 as a marker for invasive colorectal cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  A. Goldberg,et al.  Proteasome inhibitors: from research tools to drug candidates. , 2001, Chemistry & biology.

[72]  C. Pickart,et al.  Mechanisms underlying ubiquitination. , 2001, Annual review of biochemistry.

[73]  L. Petrucelli,et al.  Co-association of parkin and alpha-synuclein. , 2001, Neuroreport.

[74]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.